An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors
- 29 September 2010
- journal article
- clinical trial
- Published by Wiley in Cancer Cell
- Vol. 88 (5), 652-659
- https://doi.org/10.1038/clpt.2010.158
Abstract
Pazopanib, an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro. This study in patients with advanced cancer evaluated the effect of pazopanib on CYP450 function by comparing the pharmacokinetics of CYP-specific probe drugs in the presence and absence of pazopanib. The probes used included midazolam (CYP3A specific), warfarin (CYP2C9 specific), omeprazole (CYP2C19 specific), caffeine (CYP1A2 specific), and dextromethorphan (CYP2D6 specific). The estimated ratios of the geometric means (90% confidence interval (CI)) for the area under the curve to the last measurable point (AUC(0-t)) for these probe drugs with/without pazopanib were as follows: midazolam, 1.35 (1.18-1.54); omeprazole, 0.81 (0.59-1.12); caffeine, 1.00 (0.77-1.30); and S-warfarin, 0.93 (0.84-1.03). The geometric least-squares (LS) mean ratio of urine dextromethorphan:dextrorphan ranged from 1.33 (0-4-h interval) to 1.64 (4-8-h interval). The data suggest that pazopanib is a weak inhibitor of CYP3A4 and CYP2D6 and has no effect on CYP1A2, CYP2C9, and CYP2C19 in patients with advanced cancer.Keywords
This publication has 16 references indexed in Scilit:
- Phase I Trial of Pazopanib in Patients with Advanced CancerClinical Cancer Research, 2009
- CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeBritish Journal of Cancer, 2008
- Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor InhibitorJournal of Medicinal Chemistry, 2008
- PhRMA White Paper on ADME PharmacogenomicsThe Journal of Clinical Pharmacology, 2008
- New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance ProcessThe Journal of Clinical Pharmacology, 2008
- Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian PopulationsClinical Pharmacology & Therapeutics, 2008
- Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 CocktailThe Journal of Clinical Pharmacology, 2006
- Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”Clinical Pharmacology & Therapeutics, 2003
- Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase responseBritish Journal of Cancer, 2002
- Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N -acetyltransferase-2, and xanthine oxidase with the ″Cooperstown cocktail”Clinical Pharmacology & Therapeutics, 2000